Table 2. Clinical characteristics of EGFR exon 19 deletion patients with NSCLC who had dynamic plasma collected (n = 36).
| Characteristic | Patients (n = 36) |
|---|---|
| Age (years), mean (range) | 51.3 (41–72) |
| Sex, n (%) | |
| M | 17 (47.2) |
| F | 19 (52.8) |
| ECOG PS, n (%) | |
| 0 | 0 (0.0) |
| 1 | 36 (100.0) |
| 2 | 0 (0.0) |
| Complications, n (%) | |
| Y | 9 (25.0) |
| N | 27 (75.0) |
| Smoker, n (%) | |
| Y | 7 (19.4) |
| N | 29 (80.6) |
| FH of cancer, n (%) | |
| Y | 3 (8.3) |
| N | 33 (91.7) |
| cStage, n (%) | |
| IIIA–B | 2 (5.5) |
| IV | 34 (94.5) |
| Histology, n (%) | |
| ADC | 35 (97.2) |
| ADC+SCC | 1 (2.8) |
| EGFR-TKI treatment, n (%) | |
| Gefitinib | 19 (52.8) |
| Erlotinib | 1 (2.8) |
| Icotinib | 16 (44.4) |
| Line of EGFR-TKI treatment, n (%) | |
| First | 28 (77.8) |
| Second | 8 (22.2) |
| Best response to EGFR-TKI treatment, n (%) | |
| CR | 1 (2.8) |
| PR | 23 (63.9) |
| SD | 11 (30.5) |
| PD | 1 (2.8) |
| Sample collected during EGFR-TKI treatment, n (%) | |
| Y | 36 (100.0) |
| N | 0 (0.0) |
| Sample collected at the time of PD on EGFR-TKI treatment, n (%) | |
| Y | 12 (33.3) |
| N | 24 (66.7) |
Abbreviations: ADC, adenocarcinoma; CR, complete response; cStage, clinical stage; ECOG, Eastern Cooperative Oncology Group; F, female; FH, family history; M, male; N, no; PS, performance status; SCC, squamous cell carcinoma; Y, yes